ArticleLipids in health and disease2016
High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease.
Article in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Cross-ancestry analyses of Chinese and European populations reveal insights into the genetic architecture and disease implication of metabolites.Cell genomics · 2025Pooled it
- Serum pentraxin-3 in patients with chronic obstructive pulmonary disease: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis.Lipids in health and disease · 2018Pooled it
- Apolipoprotein M: Structural insights, functional roles, and therapeutic approaches in vascular disease.The Journal of biological chemistry · 2026Review
- Association of hs-CRP/HDL, AIP and NHHR with chronic obstructive pulmonary disease: a cross-sectional NHANES study.Annals of medicine · 2025Article
- Observational and Genetic Evidence Reveals the Effect of Serum Lipid Levels on COPD Risk.International journal of chronic obstructive pulmonary disease · 2025Observational
- Causal Relationships Between Blood Lipid Levels and Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Analysis.International journal of chronic obstructive pulmonary disease · 2025Article
- Article
- Proteomic associations with forced expiratory volume: a Mendelian randomisation study.Respiratory research · 2024Article
- Article
- Low-density lipoprotein cholesterol and risk of COPD: Copenhagen General Population Study.ERJ open research · 2023Article
- High-Density Lipoproteins in Non-Cardiovascular Diseases.International journal of molecular sciences · 2022Article
- High-Density Lipoproteins: A Role in Inflammation in COPD.International journal of molecular sciences · 2022Review
- Differential Expression of Serum Proteins in Chronic Obstructive Pulmonary Disease Assessed Using Label-Free Proteomics and Bioinformatics Analyses.International journal of chronic obstructive pulmonary disease · 2022Article
- Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2021Review
- Apolipoprotein M promotes the anti-inflammatory effect of high-density lipoprotein by binding to scavenger receptor BI.Annals of translational medicine · 2020Article
- Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease.Respiratory research · 2020Article
- The Relationship of Lymphocyte to High-Density Lipoprotein Ratio with Pulmonary Function in COPD.International journal of chronic obstructive pulmonary disease · 2020Article
- Lipid metabolism in chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2019Review
- Apolipoprotein M Serum Levels Correlate with IgA Vasculitis and IgA Vasculitis Nephritis.Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, variations in a component of high-density lipoprotein (HDL), namely apolipoprotein M (apoM), were found to be associated with chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate the association between apoM and COPD severity. Factors associated with apoM, COPD, or coronary artery disease (CAD) were also assessed.
methodsA total of 110 COPD patients and 110 age- and sex-matched non-COPD controls were included. Among them, thirty COPD patients and seven non-COPD controls had CAD. ApoM and pentraxin-3 levels were measured by ELISA. Additionally, the levels of high-sensitivity C-reactive protein (hs-CRP), cholesterol, and triglyceride were assessed using an automatic biochemical analyzer.
resultsSerum apoM levels increased gradually with COPD severity, with the most prominent apoM elevation observed in very severe COPD cases. In addition, ApoM was correlated with percent-predicted forced expiratory volume in one second (% predicted FEV1) (r = -0.38, P < 0.001), low-density lipoprotein cholesterol (LDL-C) (r = 0.23, P < 0.017), and hs-CRP (r = 0.24, P = 0.01) in COPD patients. Furthermore, apoM was shown to be a risk factor for COPD onset (OR = 1.095, 95% CI = 1.034-1.160, P = 0.002), but not associated with CAD in COPD patients.
conclusionsSerum apoM was elevated in COPD patients and increased gradually with COPD severity. However, there was no association between apoM and CAD development in COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.